Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Affiliation
Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United KingdomIssue Date
2018-08-10
Metadata
Show full item recordCitation
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. 2018, BloodJournal
BloodDOI
10.1182/blood-2018-05-851824PubMed ID
30097508Type
ArticleLanguage
enISSN
1528-0020ae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-05-851824
Scopus Count
Collections
Related articles
- The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
- Authors: Chen X, Hong Y, Zheng P, You X, Feng J, Huang Z, Wang Y
- Issue date: 2020 Jan 15
- PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
- Authors: Tang FF, Lu SY, Zhao XS, Qin YZ, Liu XH, Jia JS, Wang J, Gong LZ, Jiang Q, Zhao T, Shi HX, Chang YJ, Huang XJ, Jiang H
- Issue date: 2021 Dec
- ATRA plus arsenic gets another "A" in APL.
- Authors: Park JH
- Issue date: 2012 Aug 23
- [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
- Authors: Creutzig U, Dworzak M, von Neuhoff N, Rasche M, Reinhardt D
- Issue date: 2018 Oct
- Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
- Authors: Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F
- Issue date: 2025 Jan 1